NCM Boston

NCM Boston

Subscribe

Oxford Nanopore Technologies

Bradley Hall

Bradley Hall
Job title
Institution
Asuragen, USA
Biography

Bradley Hall received his PhD in molecular biology from The University of Texas in 2008. There, he developed the Aptamer Stream within the Freshman Research Initiative, the largest undergraduate research program in the US. He transitioned to Altermune Technologies in 2010, founded by Nobel laureate Kary Mullis, where he focused on immune-redirecting therapies. In 2016, Brad joined Asuragen where he is currently Director of R&D with work focused on advancing nanopore sequencing in clinical laboratories with accessible testing kits.

Recent publications

Hall, B. et al. A dual-mode targeted nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis. medRxiv 2024.02.22.24303180; (2024).
DOI: 10.1101/2024.02.22.24303180

Hall B. et al. Multisite Verification of a Targeted CFTR Polymerase Chain Reaction/Capillary Electrophoresis Assay That Evaluates Pathogenic Variants Across Diverse Ethnic and Ancestral Groups. Arch Pathol Lab Med. (2024).
DOI: 10.5858/arpa.2023-0230-OA.

Talks at this conference

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
English flag